‘API prices/ volume growth to remain weak in FY25’
India Ratings and Research forecasts weak API prices and volume growth for India in FY25 due to imports and competition from China. However, low raw material costs and forward integration into formulations have led to improved EBITDA margins. A broader product range has also resulted in strong financial performance for Ind-Ra rated pharma companies.